# Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

> **NCT00840216** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Clarithromycin ER 500 mg tablets
- **DRUG:** BIAXIN® XL 500 mg tablets

## Key facts

- **NCT ID:** NCT00840216
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840216, "Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00840216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*